Image For Activity Cover
Challenges in Diagnosing and Managing Patients with Fibrodysplasia Ossificans Progressiva
Course Description
This recording of a virtual live session at Clinical Endocrinology Update 2021 focuses on clinical presentations on the state of care, challenges, and emerging therapies on Fibrodysplasia ossificans progressiva.
Target Audience
The intended audience for this activity is endocrinologists and other health care providers diagnosing and managing individuals with FOP.
Learning Objectives
Upon successful completion these educational sessions, participants should be better able to:
  • Analyze clinical presentations of FOP in individuals.
  • Review the importance of early diagnosis and management of FOP
  • Describe the best practices in management of patients with FOP
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.50 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Faculty and Disclosures

Kelly L. Wentworth, MD - Program Chair
University of California, San Francisco
Assistant Adjunct Professor
San Francisco, CA

Mona Al Mukaddam, MD, MS
Associate Professor of Clinical Medicine and Orthopaedic Surgery
Director of the Penn Bone Center
Ian Cali Clinical Scholar at the Center for Research in FOP & Related Disorders
Penn Medicine University City
Philadelphia, PA

Elisabeth M.W. Eekhoff, MD PhD
Amsterdam UMC location Vumc
Medical Specialist, Internal Medicine (VUmc)
Medical Specialist, Amsterdam Gastroenterology Endocrinology Metabolism (VUmc)
Medical Specialist, AMS - Musculoskeletal Health (VUmc)
Medical Specialist, AMS - Tissue Function & Regeneration
Amsterdam, The Netherlands

Benjamin Levi, MD
UT Southwestern Medical Center
Associate Professor
Boston, MA

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

  • Mona Al Mukaddam, MD, MS: Research Investigator, Clementia/Ipsen pharmaceuticals, Regeneron
  • Kelly L. Wentworth, MD: Research Investigator, Ipsen pharmaceuticals
  • Elisabeth M.W. Eekhoff, MD, PhD: Grants/Funding, IFOPA, Dutch FOP patients organization, Regeneron, EU-AZ, Ipsen


The following faculty reported no relevant financial relationships:

  • Benjamin Levi, MD

The following committee memb who planned and reviewed content for this activity reported no relevant financial relationships:

  • Kelly Lauter Roszko, MD, PhD

The following committee member reported relevant financial relationships:

  • Andjela T. Drincic, MD: Advisory Board Member, Corcept

The following committee members reported no relevant financial relationships: 
Howard S. Blank, MD; Beret Ann Casey, MD; Lediya Cheru, MD; Marcelo Correia, MD, PhD; Soleymani Taraneh, MD; and Savitha Subramanian, MD, Sowmya Suryanarayanan, MD

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.


ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by educational grant from Ipsen Biopharmaceuticals, Inc.

Summary
Availability: On-Demand
Available Sep 20, 2021 to Sep 30, 2022
Cost : FREE
Credit Offered:
1.5 AMA PRA Category 1 Credits
1.5 ABIM-MOC Points
1.5 Participation Credits
Recommended
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Powered By